Cognitive Benefits Seen With Leafy Green Vegetable Intake

Share this content:
Cognitive Benefits Seen With Leafy Green Vegetable Intake
Cognitive Benefits Seen With Leafy Green Vegetable Intake

WEDNESDAY, Dec. 20, 2017 (HealthDay News) -- Intake of primary nutrients and bioactives in green leafy vegetables is associated with slower cognitive decline, according to a study published online Dec. 20 in Neurology.

Martha Clare Morris, Sc.D., from Rush University in Chicago, and colleagues conducted a prospective study involving 960 participants of the Memory and Aging Project, ages 58 to 99 years, who completed a food frequency questionnaire and had two or more cognitive assessments over a mean of 4.7 years.

The researchers found that consumption of green leafy vegetables was correlated with slower cognitive decline in a model adjusted for confounding variables; those in the highest quintile of intake (median 1.3 servings/day) had a decline rate that was β = 0.05 standardized units slower, equivalent to being 11 years younger in age. Individual associations with slower cognitive decline were seen for higher intakes of each of the nutrients and bioactives except β-carotene. The rates for the highest versus the lowest quintiles of intake in adjusted models were β = 0.02 for phylloquinone, β = 0.04 for lutein, β = 0.05 for folate, β = 0.02 for α-tocopherol, β = 0.04 for nitrate, β = 0.04 for kaempferol, and β = 0.02 for β-carotene, with the latter rate being nonsignificant.

"Consumption of approximately one serving per day of green leafy vegetables and foods rich in phylloquinone, lutein, nitrate, folate, α-tocopherol, and kaempferol may help to slow cognitive decline with aging," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »